Skip to content

MDMA: all studies

Page 268 of 346: studies 2,671 to 2,680 of 3,454, newest first. Back to the MDMA overview

Research

A systematic review of income and education reporting in psychedelic clinical trials

Nature Mental Health May 1, 2025 Daniel H. Grossman, Kevin R. Madden, Nicky J. Mehtani et al. 10 citations

Socioeconomic status (SES) substantially influences mental health outcomes and treatment access, yet its reporting in psychedelic-assisted therapy trials remains underexplored. Here we systematically reviewed 98 articles (49 primary trials and 49 secondary analyses) published between 2006 and 2024 examining classic psychedelics and MDMA for mental health conditions. Only 12% of primary trials...

Utilizing Caenorhabditis Elegans as a Rapid and Precise Model for Assessing Amphetamine-Type Stimulants: A Novel Approach to Evaluating New Psychoactive Substances Activity and Mechanisms.

Advanced Science May 1, 2025 Yuanpeng Li, Hongyuan Li, Hongshuang Wang et al. 3 citations

The surge of new psychoactive substances (NPS) poses significant public health challenges due to their unregulated status and diverse effects. However, existing in vivo models for evaluating their activities are limited. To address this gap, this study utilizes the model organism Caenorhabditis elegans (C. elegans) to evaluate the activity of amphetamine-type stimulants (ATS) and their analogs....

DOI: 10.1002/advs.202500808 (opens in new tab) Full text (opens in new tab) Behavioral testing Pharmacology Amphetamine‐type stimulants New psychoactive substances +4

An Update on Psychotherapy for the Treatment of PTSD.

American Journal of Psychiatry May 1, 2025 Barbara Olasov Rothbaum, Laura E Watkins 13 citations

Posttraumatic stress disorder (PTSD) symptoms are part of the normal response to trauma. Most trauma survivors will recover over time without intervention, but a significant minority will develop chronic PTSD, which is unlikely to remit without intervention. Currently, only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration to treat PTSD, and the...

DOI: 10.1176/appi.ajp.20250110 (opens in new tab) Full text (opens in new tab) PTSD Treatment Trauma therapy Mental health interventions Evidence-based psychotherapy +1

Recreational Ketamine Use among Individuals with Opioid Use Disorder: Demographics, Motivations, and Polysubstance Use.

Substance Use & Misuse May 1, 2025 Corinne L Chandler, Mance E Buttram, Matthew S Ellis 1 citation

Data show that recreational ketamine use appears to be increasing. This study aimed to understand how ketamine fits into broader polysubstance use in individuals with opioid use disorder (OUD). Survey data were collected from a sample of treatment-seeking individuals with OUD in March 2022. Of 301 respondents, 28.6% reported lifetime ketamine use. Ketamine use was more frequently reported among...

An online study to understand chemsex in India.

Indian Journal of Psychiatry May 1, 2025 Varsha Sriperambudoori, Siddharth Sarkar, Anju Dhawan 4 citations

While chemsex has been studied in several parts of the world, it has been an under-studied area in India. Anecdotally, use of substances in the context of sexual encounters has been increasing in India, especially in the population of men having sex with men. In the background of limited literature in India, this online survey aimed to assess facets related to chemsex in the country. This...

DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_1121_24 (opens in new tab) Full text (opens in new tab) Chemsex Methamphetamine Hiv/aids/human immunodeficiency virus Lgbtq+/sexual minorities/gender minorities/queer +1

The Difference between an Entheogen and Synthetic Psychedelic

April 28, 2025 Charmaine Husum

This chapter explores the key differences between entheogens and synthetic psychedelics, focusing on their origins, cultural contexts, and effects on consciousness. Entheogens are naturally occurring substances, such as psilocybin, ayahuasca, and peyote, traditionally used by Indigenous cultures for spiritual and healing purposes. These substances are often consumed in ceremonial settings with...

The role of mitochondrial dysfunction and calcium dysregulation in 2C-I and 25I-NBOMe-induced neurotoxicity.

Chemico-Biological Interactions April 25, 2025 Eva Gil-Martins, Fernando Cagide, Ana Borer et al. 4 citations

New psychoactive substances (NPS) are designed to evade legal regulation while mimicking the effects of classic illicit drugs such as 3,4-methylenedioxymethamphetamine (MDMA). This category includes phenethylamine derivatives, such as the psychedelic 2C and NBOMe drugs. Given the lack of data regarding the toxicological profile of these substances, the goal of this study was to evaluate the...

DOI: 10.1016/j.cbi.2025.111425 (opens in new tab) Full text (opens in new tab) 2c drugs Nbome drugs New psychoactive substances Sh-sy5y cells +5

Regulatory Challenges of Integrating Psychedelics into Mental Health Sector

Psychoactives April 22, 2025 Kerem Kemal Soylemez, Emma Marie de Boo, Joanne Lusher 7 citations

Psychedelic substances have recently emerged as a promising method for treating mental health conditions, despite a history of stigmatization and restriction in use. The present review synthesizes existing literature on the therapeutic potential of psychedelics such as LSD, psilocybin, and MDMA in addressing specific mental health conditions like depression, anxiety, and addiction. On reviewing...

Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress

Psychedelic Medicine April 22, 2025 Sean M. Viña 6 citations

Objective: Prior research has found an association between psychedelic use and reduced stigma attached to mental illness. However, whether psychedelics alleviate stigma-related distress remains unclear. Since stigma impacts different groups uniquely, any moderating effect of psychedelics on stigma-related distress is likely to vary across subpopulations. This study addresses two main questions:...

Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.

Brain Sciences April 22, 2025 Fabrizio Schifano, Stefania Bonaccorso, Davide Arillotta et al. 14 citations

Background: "Chemsex" involves the intake of a range of drugs (e.g., synthetic cathinones, gamma-hydroxybutyric acid/gamma-butyrolactone (GHB/GBL), ketamine, methamphetamine, "poppers", type V phosphodiesterase (PDE) inhibitors, MDMA/ecstasy, cocaine, cannabis, and occasionally a few other molecules as well, to enhance and prolong sexual experiences. This paper aims to provide an overview of...

DOI: 10.3390/brainsci15050424 (opens in new tab) Full text (opens in new tab) Substance abuse Sexual health Chemsex Drug addiction +4